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RESEARCH ARTICLE Open Access
Relevance of internal time and circadian
robustness for cancer patients
Elisabet Ortiz-Tudela1,2,4, Pasquale F. Innominato2,3, Maria Angeles Rol1,5*, Francis Lévi2,3,4
and Juan Antonio Madrid1
Abstract
Background: Adequate circadian timing of cancer treatment schedules (chronotherapy) can enhance tolerance
and efficacy several-fold in experimental and clinical situations. However, the optimal timing varies according to sex,
genetic background and lifestyle. Here, we compute the individual phase of the Circadian Timing System to
decipher the internal timing of each patient and find the optimal treatment timing.
Methods: Twenty-four patients (11 male; 13 female), aged 36 to 77 years, with advanced or metastatic gastro-intestinal
cancer were recruited. Inner wrist surface Temperature, arm Activity and Position (TAP) were recorded every 10 min for
12 days, divided into three 4-day spans before, during and after a course of a set chronotherapy schedule. Pertinent
indexes, I < O and a new biomarker, DI (degree of temporal internal order maintenance), were computed for each
patient and period.
Results: Three circadian rhythms and the TAP rhythm grew less stable and more fragmented in response to treatment.
Furthermore, large inter- and intra-individual changes were found for T, A, P and TAP patterns, with phase
differences of up to 12 hours among patients. A moderate perturbation of temporal internal order was observed,
but the administration of fixed chronomodulated chemotherapy partially resynchronized temperature and activity
rhythms by the end of the study.
Conclusions: The integrated variable TAP, together with the asynchrony among rhythms revealed by the new
biomarker DI, would help in the personalization of cancer chronotherapy, taking into account individual circadian
phase markers.
Keywords: Circadian, gastro-intestinal cancer, personalization, TAP, chemotherapy
Background
The circadian system controls the timing of all processes
in the organism and is composed of a set of structures
whose core piece lies in the suprachiasmatic nuclei of
the hypothalamus (SCN) [1]. Impairment of the bio-
logical clock has been associated with an increased risk
of developing several diseases, such as cancer, cognitive
impairments, metabolic syndrome, cardiovascular dys-
function and immune dysregulation [2]. Moreover, circa-
dian disruption has been reported to decrease survival of
cancer patients [3–5]. This concern is so great that the
International Agency for Research on Cancer has classi-
fied long-term shift work involving circadian disruption
in Group 2A, meaning that it is “probably carcinogenic
to humans” [6].
Knowledge of the rhythmic features of drug metabolism,
cellular detoxification and cell division cycle [7] has been
used to optimize cancer treatments by means of chrono-
therapy. Chronotherapy mainly involves chronomodulated
delivery schedules, and consists of the administration of
each drug according to a delivery pattern with precise
circadian times in order to achieve the best tolerance
and efficacy [8]. However, simpler approaches deliver-
ing a conventional treatment either during the morning
or during the afternoon have also been reported [9, 10].
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Scheduled cancer chronotherapy has proven to be a reli-
able and advantageous alternative to fixed chemotherapy
schedules, at least in men [8, 11]. However, according to
previous papers from our group, chemotherapy adminis-
tration produces an overall disturbance in the rest-activity
rhythm, while different patterns of evolution are evident
among patients [12]. Furthermore, an effect of sex on the
efficacy of the treatment has also been reported [13, 14],
suggesting that efficacy could be theoretically improved by
personalizing treatment schedules through the use of indi-
vidual circadian phase markers, as opposed to general
schedules common to all patients [7, 8, 11, 12].
However, the introduction of personalized treatments
should take into account circadian characteristics,
which can differ not only according to the individual
person, but also depending on his/her sex, age and
chronotype [15–19]. The knowledge of the individual
circadian system robustness could in theory, first, allow
us to determine which patients might benefit from a
chronomodulated therapy and second, to customize the
particular timing of the chronotherapy to match up
with the personal circadian time.
Nevertheless, assessing the individual circadian status
and the severity of chronodisruption is still an unre-
solved issue, since there are not enough studies on
humans attempting to decipher internal timing. Several
studies have monitored the rest-activity rhythm as a bio-
marker of circadian functions in humans (for a review,
see [20]), since this can be non-invasively recorded, even
for extended periods of time using a wrist-worn acceler-
ometer (actigraph), thus making it suitable for applica-
tion in the oncology setting [20]. However, it presents
certain limitations because of the existence of strong ex-
ogenous influences from the type and timing of activity
schedules and artifacts, such as those related to bed
partner movements or sleeping when travelling in a car
or train, etc. [21, 22].
Core body temperature (CBT) is another circadian
marker rhythm whose pattern is generated by the
suprachiasmatic nuclei, which also acts as an effector
involved in the internal coordination of peripheral
clocks. However, its evaluation is not problem-free: the
CBT rhythm can be determined using a rectal probe
connected to an external recorder [23, 24] (a system
that is neither safe nor convenient for ambulatory as-
sessment of rhythms in cancer patients) or telemetric
pills (which are very expensive and provide records that
are too short). Thus, the topic of non-invasive ambulatory
monitoring is attracting increasing interest, with distal
skin temperature presently constituting a feasible alterna-
tive to CBT [25–27]. The peripheral skin temperature
pattern is roughly opposite that of CBT: the highest
temperatures occur during early night, while the lowest
values are seen in the early morning, after awakening
[27]; however, it is important to note that this can be
masked by position or activity [28].
For this reason, the combination of different comple-
mentary circadian markers in the integrated variable
TAP (Temperature, Activity, body Position) is less af-
fected by masking factors than individual variables, and
minimizes individual recording artifacts. Thus, its use
has been reported to estimate the functional status of
the circadian system under real life conditions [26] and
to assess the sleep-wake cycle, obtaining better estimates
than actigraphy alone [29]. Furthermore, TAP has been
correlated to the melatonin rhythm, as a M5 calculated
on TAP and the Dim Light Melatonin Onset (DLMO),
considered to be the most robust phase marker, pre-
sented a correlation coefficient of 0.720 (p = 0.006) [30].
Moreover, the simultaneous recording of multiple overt
rhythms allows us to assess their internal synchrony,
constituting a first approach to evaluating whether tem-
poral order is maintained.
The aim of the current study was to evaluate concomi-
tantly multiparametric TAP in cancer patients undergoing
fixed-scheduled chronotherapy. The primary endpoint
was to evaluate the individual circadian phase and ro-
bustness at baseline. Secondary outcomes included the
dynamic and continuous evaluation of chemotherapy-
induced changes, the degree of internal rhythmic
synchronization and the associations between baseline
and on-treatment circadian parameters and clinical
outcomes. This novel and unique tool provides rele-
vant information needed to precisely optimize chrono-
therapy based on the patient's individual phase, in
order to improve its therapeutic index.
Methods
Study design
A descriptive, exploratory and repeated measures de-
sign was implemented in order to evaluate the dynam-
ics of three biomarkers (Temperature, Activity and
Position) of the Circadian Timing System (CTS) in can-
cer patients receiving a multidrug, 5-Fluorouracil-based
cancer chronotherapy protocol [31]. The three circa-
dian biomarkers were jointly recorded for 12 days, i.e.
during a baseline 4-day span before chronotherapy on-
set, and over the next 8 days, which corresponded to
treatment administration and early recovery. This re-
cording was scheduled to take place at least 2 weeks
after the previous chemotherapy cycle. The present
study was approved by the hospital's internal review
board and ethics committee and abided by the Helsinki
Declaration of 1975 (revised in 1983). All the subjects
were recruited at the Chronotherapy Unit of the Oncol-
ogy Department in Paul Brousse Hospital (Villejuif,
France). After full explanation of the procedure and
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objectives and before being enrolled in the study, all pa-
tients gave their oral consent to participate in it.
Eligibility criteria
Eligibility criteria included a histological proof of solid
cancer at an advanced or metastatic stage. Patients had to
be at least 18 years old, with a physician-rated Perform-
ance Status (PS) of less than 3 according to the World
Health Organization (W.H.O.) classification, and an esti-
mated life expectancy of at least 6 months. Study entry
required Grade < 3 in acute clinical and hematological ad-
verse events (National Cancer Institute Common Toxicity
Criteria v3.0) and a treatment-free interval of at least
2 weeks. Non-inclusion criteria were persistent grade 3-4
chronic toxicities (except alopecia), symptomatic brain
metastases, concomitant severe infection, surgery during
the previous month, severe heart dysfunction or ischemic
disease and uncontrolled psychiatric illness.
Chemotherapy regimens
Non-hospitalized patients received one of four set 4-day
multidrug chronotherapy protocols selected according to
disease type and status [14, 32, 33]. The use of a multi-
channel portable and time-programmable infusion pump
(Mélodie®, Aguettant, France) enabled fixed-time chron-
omodulated infusions of 5-fluorouracil-leucovorin (5-
FU-LV; delivered from 22:15 to 9:45, with peak rate at
4:00), oxaliplatin (l-OHP, delivered from 10:15 to 21:45,
with peak rate at 16:00) and/or irinotecan (CPT-11, deliv-
ered from 2:00 to 8:00, with peak rate at 5:00) [14, 32, 33].
As indicated, cetuximab, panitumumab, bevacizumab, or
docetaxel were administered over 1-2 h in the outpatient
clinic, prior to chronotherapy onset.
Toxicity assessment
Physical examination and toxicity assessment according
to NCI CTC-AE v3.0 criteria were performed both at
baseline and prior to the administration of the subse-
quent treatment course. Blood cell counts were ob-
tained before chronotherapy and weekly thereafter,
while blood chemistry was determined at baseline and
at 2 or 3 weeks. Treatment-induced grade 1 body
weight loss and/or grade 2 fatigue were considered to
be relevant toxicities, in view of their prior association
with both circadian disruption and outcomes of chrono-
therapy [3, 12, 34].
Circadian biomarkers
The wrist temperature rhythm was continuously assessed
every 10 min for 12 days using a temperature sensor
(Thermochron® iButton DS1921H, Dallas, Maxim Inte-
grated). It was attached within a double-sided cotton sport
wrist band, with the sensor surface placed over the radial
artery of the non-dominant hand [26–28, 30].
The body position and rest-activity rhythms were de-
termined every 30 seconds over the same 12 days by an
accelerometer inserted into a sports band. Its x-axis was
set parallel to the humerus bone of the non-dominant
arm (Hobo® Pendant G Acceleration Data Logger,
Massachusetts, Onset Computer Corporation) [26].
Furthermore, patients were asked to complete a diary
with their daily activities such as the awakening mo-
ment, main meal times, naps and going-to-bed times
during the whole study.
Biomarker data transformation
The integrated TAP variable was computed as described
in [26]. Briefly, wrist temperature (T), motor activity (A)
and body position (P) data were normalized so that all
values ranged between 0 and 1, after removing artifacts.
High skin temperature values are usually found at night,
when activity counts and position level data are lowest
[26]. Therefore, wrist temperature values were inverted
so that all three biomarkers appear with a similar pattern
of higher counts during daytime. The mean of the nor-
malized variables (T, A and P) was calculated for each
subject. TAP values near 1 support a high activation
level, as indicated by a low wrist temperature, a high
level of activity and a vertical position. In contrast, near-
null values correspond to a deep rest state, as indicated
by a high wrist temperature, a low activity level and a
horizontal position.
Time series analyses
The multiparametric recordings allowed the computa-
tion of the following nine parameters for each individual
circadian biomarker and the integrated variable TAP at
baseline, during chronotherapy, and during the early re-
covery period [28, 35]:
– Phase markers, including the mean value and timing
of five consecutive hours with the lowest values (VL5
and L5, respectively) and the mean value and timing of
ten and five consecutive hours with the highest values
(VM10 and M10, and VM5 and M5, respectively).
The phase markers allowed the computation of the
relative amplitude (RA), which is the difference
between the VM10 and VL5, divided by VM10 +VL5.
To facilitate comparisons among variables, this
parameter was multiplied by ten for wrist temperature.
– Interdaily Stability (IS), which provides an estimated
measure of rhythm stability, ranging between 0
(Gaussian noise) to 1 (perfect rhythm stability from
one day to the next).
– Intradaily Variability (IV), which is an estimated
measure of rhythm fragmentation, with values of 0
indicating a perfectly sinusoidal curve, and 2
Gaussian noise, respectively.
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IV, IS and RA were incorporated into a single variable
to yield the Circadian Function Index (CFI). CFI can be
calculated as described in [26]. It oscillates between 0
(absence of circadian rhythmicity) and 1 (a robust circa-
dian rhythm).
Each of these parameters was computed before, after
and during chemotherapy. In addition, we generated full
study representations (Figs. 1 and 2) of all variables ana-
lyzed, as well as mean waveforms for every period of
study.
Furthermore, in order to explore the maintenance or
alteration of internal temporal order [36] in cancer
patients, we calculated the absolute difference between
the phase markers M5 (for temperature) and L5 (for
activity) for each patient and each period studied. In an
ideal situation, both phase markers (midpoint of
maximal temperatures and minimal activity) should be
synchronized; in the worst case scenario, a 12-hour
difference would be found between them. Thus, when dif-
ferences reached 12 hours, the internal Desynchronization
Index (DI) was considered to be 1. When no timing differ-
ence was found, DI was 0. Timing differences between 0
and 12 hours were proportionally assigned a value
between 0 and 1.
Fig. 1 Twelve-day ambulatory mean recording of TAP (a), wrist temperature (b), motor activity (c) and body position (d) (n = 24) during the study
period. The mean of each variable is represented as a black line, and the SEM as a vertical grey line. Rest declared denotes the percentage of
patients that declared being asleep at each time point, and is represented as a grey area on each graph for terms of comparison. The
chemotherapy period is highlighted by a light grey square
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Statistical analyses
The primary endpoint was the distribution of the circa-
dian phase and robustness parameters at baseline, and
their clinical determinants. To this end, descriptive sta-
tistics were performed first. Second, differences in T, A,
P and TAP parameters at baseline were assessed accord-
ing to clinical features, using non-parametric tests
(Kruskal-Wallis or Mann-Whitney) for ordinal variables
(sex, PS, prior chemotherapy) and the Pearson correl-
ation test for quantitative variables (age).
For secondary endpoints, descriptive statistics were
obtained for each parameter in every time span. Com-
parisons between the distribution of the parameters ac-
cording to time span and sex were made using a
repeated measures ANOVA, with sex as a factor (signifi-
cance level set at p < 0.05), followed by Bonferroni post
hoc pairwise comparisons when appropriate.
Logistic regression was used to explore the predictive
value of baseline CFI or DI for the occurrence of clinically
relevant toxicities during the same course of chemotherapy.
Associations between toxicity and chemotherapy-induced
circadian disruption during or after chemotherapy adminis-
tration were examined using a Kolmogorov-Smirnov Z test.
Given the exploratory nature of this analysis, the signifi-
cance level was set at p < 0.05.
Wherever appropriate, data in texts and figures are
expressed as mean ± SEM. Statistical analyses were per-
formed using the PASW Statistics 18 program (SPSS,
IBM, USA).
Results
Patient characteristics
Twenty-four patients were enrolled in the study, including
13 women and 11 men aged 36 to 77 years (Table 1). The
majority of the patients had metastatic colorectal cancer
(21 patients, 88 %), a PS of 0 (18 patients, 75 %) and had
received prior chemotherapy (17 patients, 71 %). Sixteen
patients (67 %) were given the 4-drug chronotherapy regi-
men combining irinotecan, oxaliplatin, and 5-FU-LV.
Fig. 2 Mean waveforms for each variable and period of time studied (before = a, during = b and after = c receiving chemotherapy). The mean for
wrist temperature, motor activity, body position and TAP (n = 24) is represented as a black line with SEM as vertical grey lines. Rest declared
denotes the percentage of patients that declared being asleep at each time point; this is repeated in grey on each graph for purposes of comparison
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Monoclonal antibodies were combined with chronother-
apy for 12 patients (50 %).
Baseline circadian biomarkers
Mean waveforms for the baseline period showed coher-
ent and reasonably strong rhythmic patterns for every
variable assessed (Fig. 1, Fig. 2 and Table 2). In addition,
highest wrist temperature, lowest arm activity, lowest
position and highest TAP values occurred in the first
half of the night, as indicated by an M5 timing (± SEM)
at 03:23 ± 24 min for temperature, an L5 timing at
01:13 ± 42 min for activity, at 01:54 ± 55 min for position
and at 02:33 ± 21 min for TAP in the group of 24 patients.
Individual phase markers ranged from 22:10 to 06:30
for temperature, from 22:30 to 12:10 for activity, from
21:10 to 14:00 for body position and from 22:20 to 05:20
for TAP, thus revealing a difference of up to 12 h among
patients with extreme timings (Fig. 3).
Differences could be observed between women and
men as early as at baseline, with women always showing
stronger and less fragmented rhythms (Table 2). Thus,
IS (p = 0.002), IV (p = 0.001), RA (p = 0.001), CFI (p <
0.001) and I < O (p = 0.008) for activity, and IV (p = 0.002),
RA (p = 0.032), CFI (p = 0.021) and I < O (p = 0.032)
for TAP were significantly different between women
and men.
Circadian biomarkers during chronotherapy and
post-treatment
Overall, the fixed chronotherapy protocols, together with
non-time specified monoclonal antibodies for half of the
patients, transiently altered the baseline 24-h patterns in all
three circadian biomarkers and the integrated TAP (Fig. 1).
Treatment-induced changes included a statistically signifi-
cant increase in rhythm fragmentation (high IV) and lower
robustness (low CFI), as compared to baseline values, for
temperature, rest-activity, position and TAP (Table 2 and
Fig. 2). Similar trends were found for rhythm stability (IS)
and amplitude (RA), although the differences were not sta-
tistically significant. Complete recovery was evidenced by
data inspection after the course of chronotherapy.
Evaluation of circadian robustness
Circadian robustness was evaluated by using the CFI
from the composite variable TAP, which was previously
validated in [26]. Furthermore, we studied the coherence
of phase markers for wrist temperature and activity
rhythms throughout the study using a new index, DI or
Desynchronisation Index, which quantifies timing differ-
ences between two phase markers, M5 for wrist
temperature and L5 for activity, which should be in
phase in healthy subjects with proper internal temporal
order.
Figure 4 shows that the administration of chemotherapy
decreased the robustness of the circadian system (lower
CFI values during versus before chemotherapy), as ex-
plained by the perturbation of the wrist temperature,
motor activity and body position rhythms, while a similar
degree of desynchronization between temperature and
motor activity was maintained (similar DI values before
and during chemotherapy). However, the shock of chemo-
therapy drugs administered in a chronomodulated fashion
seemed to produce the re-synchronization of at least
temperature and activity rhythms, and a reinforcement of
circadian robustness, which was achieved after the admin-
istration of chemotherapy (Fig. 4). An example of this dis-
ruption of the temporal internal order can be found in
Fig. 5, which shows temperature and activity rhythms for
two patients.
Table 1 Characteristics of patients enrolled in the study
Age 63 y.o. (range: 37 – 78)
Sex Male 11
Female 13
Primary Tumor Colon or rectal 21
Pancreas 2
Esophagus/cardia 1
Number of metastatic sites 0 3
1 9
2 3
≥3 9
WHO-PS 0 18
1 6
2 0
Number of prior CT lines 0 7
1 2
2 6
≥3 9
CT regimen Chrono FLO 1 3
+ CETUXIMAB 1
+ DOCETAXEL 1
Chrono IF 1 1
Chrono IFL / 4
+ BEVACIZUMAB 2
+ BEVACIZUMAB + PANITUMUMAB 2
Chrono IFLO 9 16
+ CETUXIMAB 6
+ BEVACIZUMAB 1
All information was collected before the patients’ inclusion in the study and
refers to their previous medical history. Age is expressed as median and
range. CT regimen is highlighted in bold. Additional chemotherapy drugs
added to the protocol have been marked with (+), whenever necessary
WHO-PS: Performance Status according to the classification of the World
Health Organization
CT regimen: protocol followed for chemotherapy treatment. For details, please
see the material and methods section
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Table 2 IS, IV, RA, I < O and CFI calculated for wrist temperature, motor activity, body position and the composite variable TAP rhythms for the whole group (n = 24), and for
each sex
Temperature (mean ± SEM) Motor activity (mean ± SEM) Body position (mean ± SEM) TAP (mean ± SEM)
Before During After Before During After Before During After Before During After
WHOLE
GROUP
(n = 24)
IS 0.58 ± 0.04ab 0.56 ± 0.03a 0.63 ± 0.03b 0.39 ± 0.02a 0.39 ± 0.02a 0.41 ± 0.02a 0.48 ± 0.04a 0.48 ± 0.03a 0.48 ± 0.04a 0.62 ± 0.03a 0.57 ± 0.03a 0.62 ± 0.03a
IV 0.18 ± 0.02a 0.20 ± 0.02ab 0.21 ± 0.02b 1.01 ± 0.03ab 1.10 ± 0.05a 1.01 ± 0.05b 0.41 ± 0.03a 0.46 ± 0.03a 0.47 ± 0.03a 0.35 ± 0.03a 0.43 ± 0.03b 0.37 ± 0.03a
RA 0.33 ± 0.03a 0.26 ± 0.03b 0.32 ± 0.03ab 0.62 ± 0.03a 0.57 ± 0.03a 0.63 ± 0.03a 0.44 ± 0.03a 0.40 ± 0.03a 0.42 ± 0.03a 0.51 ± 0.03a 0.46 ± 0.03a 0.51 ± 0.03a
CFI 0.61 ± 0.02ab 0.57 ± 0.02a 0.62 ± 0.02b 0.50 ± 0.03a 0.47 ± 0.03a 0.51 ± 0.03a 0.57 ± 0.03a 0.55 ± 0.02a 0.56 ± 0.02a 0.65 ± 0.03a 0.60 ± 0.02a 0.65 ± 0.02a
I <
O
— — — 83.88 ± 3.22a 78.26 ± 2.93a 80.35 ± 2.63a — — — 91.61 ± 3.10a 88.74 ± 2.89a 90.71 ± 2.19a
MEN
(n = 11)
IS 0.56 ± 0.05a1 0.53 ± 0.05a1 0.63 ± 0.05a1 0.32 ± 0.02a1 0.36 ±
0.02ab1
0.40 ± 0.04b1 0.43 ± 0.07ª1 0.46 ± 0.04a1 0.47 ± 0.06a1 0.55 ± 0.04a1 0.52 ± 0.04a1 0.58 ± 0.06a1
IV 0.15 ± 0.02a1 0.18 ± 0.03ab1 0.22 ± 0.02b1 1.12 ± 0.04a1 1.17 ± 0.08a1 1.09 ± 0.08a1 0.45 ± 0.04a1 0.49 ± 0.06a1 0.55 ± 0.05a1 0.45 ± 0.04a1 0.50 ± 0.06a1 0.46 ± 0.04a1
RA 0.34 ± 0.04a1 0.28 ± 0.03a1 0.30 ± 0.03a1 0.51 ± 0.05a1 0.55 ± 0.05a1 0.55 ± 0.06a1 0.41 ± 0.06a1 0.40 ± 0.05a1 0.41 ± 0.05a1 0.44 ± 0.05a1 0.44 ± 0.05a1 0.48 ± 0.05a1
CFI 0.61 ± 0.03a1 0.58 ± 0.04a1 0.61 ± 0.03a1 0.42 ± 0.03a1 0.44 ± 0.05a1 0.47 ± 0.05a1 0.54 ± 0.05a1 0.53 ± 0.05a1 0.53 ± 0.04a1 0.59 ± 0.04a1 0.57 ± 0.05a1 0.61 ± 0.05a1
I <
O
— — — 75.04 ± 5.95a1 75.00 ± 5.76a1 76.26 ± 3.99a1 — — — 84.51 ± 6.19a1 85.61 ± 5.65a1 85.98 ± 3.77a1
WOMEN
(n = 13)
IS 0.59 ± 0.06ª1 0.58 ± 0.04a1 0.64 ± 0.04a1 0.44 ± 0.02a2 0.41 ± 0.02a1 0.42 ± 0.03a1 0.53 ± 0.04a1 0.50 ± 0.03a1 0.48 ± 0.05a1 0.68 ± 0.04a2 0.61 ± 0.03a1 0.65 ± 0.04a2
IV 0.20 ± 0.03a1 0.22 ± 0.03a1 0.19 ± 0.03a1 0.92 ± 0.03a2 1.03 ± 0.05a1 0.93 ± 0.05a1 0.37 ± 0.03a1 0.44 ± 0.03a1 0.41 ± 0.03a2 0.27 ± 0.03a2 0.37 ± 0.03b2 0.30 ± 0.02a2
RA 0.32 ± 0.04a1 0.24 ± 0.03b1 0.33 ± 0.03a1 0.71 ± 0.03a2 0.60 ± 0.05b1 0.69 ±
0.03ab2
0.47 ± 0.04a1 0.41 ± 0.04a1 0.44 ± 0.04a1 0.57 ± 0.03a2 0.47 ± 0.03b1 0.54 ± 0.04ab1
CFI 0.60 ± 0.04a1 0.57 ± 0.03a1 0.62 ± 0.03a1 0.56 ± 0.03a2 0.50 ± 0.03b1 0.55 ±
0.03ab1
0.60 ± 0.04a1 0.57 ± 0.03a1 0.57 ± 0.04a1 0.70 ± 0.03a2 0.63 ± 0.03b1 0.68 ± 0.03ab1
I <
O
— — — 91.36 ± 1.25a2 81.02 ±
2.39b1
83.82 ±
3.34ab1
— — — 97.62 ±
0.65a2
91.39 ±
2.41b1
94.72 ±
2.02ab2
Repeated-measures ANOVA and post hoc Bonferroni were performed to verify the differences among periods for the whole group or for each sex. Statistical significance was set at p < 0.05
Different letters indicate statistically significant differences between periods (also highlighted in bold.) Different numbers indicate significant differences between men and women for each variable and studied period
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Sex-dependent response of circadian biomarkers to the
fixed chronotherapy protocol
The fixed chronotherapy protocols resulted in a signifi-
cantly greater deterioration of TAP rhythms in women
than in men, despite the fact that baseline rhythms were
found to be more robust in women (Table 2). However,
this sex-dependent effect was not consistent for every
studied variable, probably due to the small sample size.
Toxicity
A single patient displayed grade 4 neutropenia. No other
hematological or clinical grade 3 or 4 toxicity was en-
countered. The most frequent adverse events consisted
of grade 1 or 2 diarrhea (67 % of the patients), fatigue
(58 %), anorexia (46 %), mucositis (46 %) and peripheral
sensory neuropathy (46 %).
A body weight loss >5 % and a fatigue ≥ grade 2 were
experienced by 5 and 9 patients, respectively, following
chronotherapy. Baseline CFI and DI did not predict the
occurrence of any toxicity. Interestingly, those patients
with this clinically relevant weight loss or fatigue dis-
played a higher DI during chronotherapy (median =
0.22), as compared to the patients without such toxic
symptoms (median = 0.10; p = 0.04).
Discussion
This study has shown for the first time that in cancer
patients the circadian system presents a huge variability
in terms of phase distribution (12 hour spread among
different patients) (Fig. 3) and more importantly, a mod-
erately perturbed temporal internal order (Fig. 4). This
was evaluated through the concomitant and continuous
measurement of 3 different circadian biomarkers (T, A,
P). This monitoring is feasible in cancer patients receiv-
ing chemotherapy on an outpatient basis, using non-
invasive devices that are readily tolerated by patients for
12 days, without significant complaints. Moreover, we
observed that the chronomodulated administration of
chemotherapy affected the robustness of the circadian
Fig. 3 Distribution of phase markers. Individual values (n = 24) for M5 (central timing for the 5 consecutive hours of maximal values), in the case
of temperature (T), or L5 (central timing for the 5 consecutive hours of minimal values) for the remaining variables (activity (A), position (P) and
TAP) in each period studied (before, during and after chemotherapy) are represented as black circles, black rhombus, white squares and black
stars, respectively. The standard nighttime period is drawn as a black bar between midnight and eight a.m.. In addition to individual values, the
mean ± SEM for each variable is also drawn in grey
Fig. 4 Relationship between the degree of desynchronization and
circadian rhythm robustness (n = 24). Relationship between the
internal temporal order desynchronization index (DI for temperature
and activity) and robustness of circadian rhythms (CFI for the
composite variable TAP) before (circle), during (square) and after
(triangle) chronotherapy in cancer patients. Data are expressed
as mean ± SEM
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system, increasing fragmentation and diminishing the
stability of wrist temperature, motor activity and body
position rhythms during the treatment (Table 2). Sur-
prisingly, the chronochemotherapy was able to partially
resynchronize the rhythms studied, leading to reduced
perturbation of the internal temporal order after the
treatment.
In cancer patients, the rest-activity rhythm has been
reported to be altered even before the administration of
chemotherapy [4, 5, 37, 38]. Previous studies have shown
that chemotherapy induces rapid-onset and sustained al-
terations in the rest-activity rhythm in most cancer
patients [12, 37, 39, 40]. The present study confirms this
finding and extends these results to wrist temperature,
body position and TAP rhythms, which were also per-
turbed to a large extent by chemotherapy.
The consequences of a disturbed circadian system in
cancer patients have been previously described with re-
spect to rest-activity and cortisol rhythms. In this sense,
having a robust rest-activity rhythm increases overall
survival [3–5]. Furthermore, a flattened cortisol rhythm
or disturbed sleep pattern in cancer patients is linked to
a higher risk of early death and shorter overall survival
[41–47]. Given the importance of these facts, future
Fig. 5 Wrist temperature and activity pattern for two patients, one with a low DI between wrist temperature and motor activity rhythms (a) and
other with a high DI (b). Mean waveforms for the baseline pre-chemo period (4 days) are represented. Wrist temperature rhythm is drawn as a
solid black line and motor activity is shown as grey bars. In addition, the five consecutive hours of maximal and minimal values for temperature
and motor activity and their central timing (M5 and L5, respectively) are indicated by grey rectangles. Wrist temperature error (the standard error
of the mean, SEM) is represented by dotted lines above and below the wrist temperature series. Motor activity SEM is omitted in this figure for
reasons of clarity. a corresponds to a patient with a DI = 0.00; note that M5 = 03:50 h and L5 = 03:50 h coincide. b corresponds to a patient with a
DI = 0.63; note not only the difference in timing for M5 = 04:40 h; L5 = 12:10 h, but also the lack of any overlapping
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studies should specifically evaluate the effect of dimin-
ishing disruption, including sleep disruption, on survival
in cancer.
A challenged internal temporal order, as observed
after long-haul transmeridian flights or rotating or
night shift work, increases the risk of developing cer-
tain types of cancer, diabetes or metabolic syndrome
and cardiovascular diseases [48, 49]. However, no data
to date are available on the internal temporal order of can-
cer patients. Here, to the best of our knowledge, we pro-
vide the first evaluation of the internal synchronization of
patients already suffering from advanced cancer. In this
study, we were able to quantify the internal rhythmic co-
herence of our patients throughout a course of chemo-
therapy. We found that, in the presence of moderate
desynchronization at baseline, chronomodulated chemo-
therapy was, on average, able to partially re-synchronize
these rhythms by the end of the study. This demonstrates
the usefulness of circadian-based chemotherapy, at least
in reducing desynchrony among the internal rhythms in
these patients. However, the limited number of pa-
tients enrolled in this study prevent for definitive con-
clusions on the clinical outcomes of prolonged internal
desynchronization. Thus, more extensive future studies
should address the implications of this finding on the
survival rates of these patients.
Sex differences in the effect of chronomodulated treat-
ments for colorectal cancer have previously been de-
scribed [13, 14]. Our results showed some rhythmic
differences according to sex but not enough to draw any
definitive conclusions. Comprehensive studies with a lar-
ger sample of patients would be needed to that effect.
The large inter-individual differences, up to 12 hours,
among patients already observed at baseline were also
found consistently throughout the study, both during
and immediately after the administration of chemother-
apy. This variability could potentially affect the safety
and efficacy of cancer treatments. The administration of
chemotherapy schedules in a chronomodulated fashion
attempts to find the optimal timing of maximum antitu-
mor activity and minimum side effects for the host [11],
which has been proven effective in both murine models
(mostly male mice) [11, 50] and humans [3, 7, 51]. Up to
now, these schedules have been administered without
considering the individual phase of each patient’s
rhythms, and thus the hypothesis of administration at
the optimal moment is challenged. Therefore, this study
establishes the proof of principle for future studies fo-
cused on the individualization of cancer treatment,
based not only on population studies, but also on indi-
vidual circadian rhythm phases.
Evidence exists in the literature regarding the benefits of
chronoenhancement in cancer patients, either through the
administration of melatonin [52], or by optimally-timed
exposure to bright light [53]. Therefore, other circadian
therapeutic approaches, including sleep hygiene and regu-
lar feeding schedules, could be implemented in order to
restore circadian function or to prevent chemotherapy-
induced circadian disruption. In mice, for example, circa-
dian amplification of the core body temperature rhythm
through meal timing has been observed to cut experimen-
tal cancer growth in half [54]. These chronoenhancement
techniques could potentially be useful to strengthen and
synchronize cancer patients’ circadian system prior to
chemotherapy administration, especially for those patients
with persistent circadian disruption. This methodology
would hypothetically, on the one hand, find the optimal
time for their treatment and on the other hand, maximize
treatment efficacy once administered at the right individ-
ual time.
Conclusions
In summary, both experimental and clinical data support
the relevance of a robust circadian system in order to en-
hance the efficacy and tolerability of chronomodulated
treatments. Thus, reliable, non-invasive and continuously
assessed circadian biomarkers, such as those provided by
the rest-activity, body position and temperature monitor-
ing computed in the integrated variable TAP are required
to optimize cancer treatments, taking into account the
status and phase of individual circadian systems. The
great inter-patient variability at baseline, during and
after treatment, and the differing profound effects of
chemotherapy on circadian robustness, phase and in-
ternal order synchronization confirm the interest of
such multiparametric evaluation of cancer outpatients.
The useful information provided by this concomitant
TAP monitoring is also relevant for interventional stud-
ies targeting the circadian timing system, in order to
enhance or protect its function, with the aim of im-
proving the wellbeing and outcomes of cancer patients.
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